MCM
MBX

Moore Capital Management’s MBX Biosciences MBX Stock Holding History

Moore Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
+64,893
New +$2.27M 0.05% 303

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Moore Capital Management's MBX Position: Q2 2026 in Review

Moore Capital Management opened a new position in MBX Biosciences (MBX) in Q2 2026: 64,893 shares worth $3.58M. The stake represents 0.05% of the portfolio and ranks #303 among its holdings.

173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Moore Capital Management held 64,893 shares of MBX Biosciences worth $3.58M as of Q2 2026.
  • MBX Biosciences was a new Moore Capital Management position in Q2 2026.
  • MBX Biosciences made up 0.05% of Moore Capital Management's portfolio in Q2 2026, its #303 holding.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.